You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲康集團(02325.HK):內地醫療系統改革將提升ICL滲透率
阿思達克 04-12 14:17
雲康集團(02325.HK)董事局主席張勇表示,目前中國醫療市場大且資源分散不均衡,單位需求遠遠未被滿足,加上社會老齡化等問題,公營醫療系統不足以應付民眾就醫需求,因此期望透過技術創新將醫療資源下沉至基層。 2021年中國獨立醫學實驗室(ICL)滲透率僅6%,對比美國達60%。他指出,檢測是臨床治療的前置工作,即是醫療系統的基礎,以往中國醫療系統以公營為主,不考核成本,但隨著當局於2021年推出按疾病診斷及病種收費的DRG/DIP制度改革,未能作為業務招徠的檢測能力將會被進一步壓縮成本,效率亦會相應提升,預料有助於檢測外包業務蓬勃發展。 雲康目前於廣州、上海、成都、合肥、南昌、昆明、濟南、貴州、南寧及深圳等地設有獨立實驗室。他表示因應ICL滲透率將提升,未來會持續擴容,並會繼續增加現場診斷中心數量。 去年度集團毛利率達34.8%,按年跌超過18個百分點。他解釋,主要由於去年新冠相關業務貢獻仍然較大,但技術提升令成本及價格大幅下降所致,又指出相關業務總量較大,雖然未來新冠相關收入會減少,但作為傳染病,其專業檢測需求不會消失。 集團去年研發投入按年增長1.15倍至9,470萬元人民幣,張勇指出,過往研發開支佔總成本約8%,基於對行業發展趨勢的判斷,未來依然會堅持對研發的投資,預期疫情後被壓抑的醫療需求將大規模恢復。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account